在需要血液透析的患者中使用萨库比特里尔-瓦尔沙坦
Dustin Le1, Morgan E Grams2, Josef Coresh3
1Division of Nephrology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland.
JAMA network open
|August 20, 2024
概括
在需要血液透析的心力衰竭患者中,sacubitril-valsartan疗法与全因死亡率和住院病例的减少有关. 这项研究为透析患者的HFrEF管理提供了关键的见解.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學.
- 药理学 药理学是指药理学的学科.
背景情况:
- 随机试验表明sacubitril-valsartan对心力衰竭有减少喷射率 (HFrEF) 的好处,但排除了透析患者.
- 患有HFrEF和需要血液透析的功能衰竭的患者代表了一个脆弱的人群,对最佳药物治疗的证据有限.
研究的目的:
- 为了比较sacubitril-valsartan对抗血管激素转化酶抑制剂 (ACEI) 或血管激素受体抑制剂 (ARB) 的有效性,在接受血液透析的HFrEF患者中.
- 评估萨库比特里尔-瓦尔萨坦对这种特定患者群体的死亡率和住院率的影响.
主要方法:
- 一个回顾性, 1:1倾向分数匹配的比较有效性研究.
- 包括18岁以上的医疗保险受益者,有血液透析的HFrEF,至少存活90天.
- 使用Cox回归模型评估了sacubitril-valsartan启动和结果之间的关联.
主要成果:
- 这项研究将1434名sacubitril-valsartan用户与1434名ACEI/ARB用户进行了匹配.
- 萨库比特里尔-瓦尔萨坦与减少全因死亡率 (HR,0.82) 和全因住院治疗 (HR,0.86) 有关.
- 在心血管死亡率或心力衰竭住院治疗方面没有观察到显著差异;高胆固醇血量下降.
结论:
- 萨库比特里尔-瓦尔萨坦疗法对需要血液透析的HFrEF患者显示出潜在的益处.
- 与改善生存率和减少住院病例有关,这表明在管理这个复杂的人口方面发挥了作用.
- 需要进一步的研究来探索最佳剂量和长期影响.
更多相关视频
16:19Heterotopic Auxiliary Rat Liver Transplantation With Flow-regulated Portal Vein Arterialization in Acute Hepatic Failure
Published on: September 13, 2014
12.7K
08:44Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
Published on: September 1, 2016
8.8K
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
405
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
405
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
642
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
642
01:22Heart Failure Drugs: Diuretics
352
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
352
01:25Antihypertensive Drugs: Direct Renin Inhibitors
513
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
513
01:11Renal Failure: Dose Adjustments
71
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
71
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K